Literature DB >> 23253779

Putting the Alzheimer's cognitive test to the test II: Rasch Measurement Theory.

Jeremy Hobart1, Stefan Cano, Holly Posner, Ola Selnes, Yaakov Stern, Ronald Thomas, John Zajicek.   

Abstract

BACKGROUND: The Alzheimer's Disease Assessment Scale-Cognitive Behavior section (ADAS-Cog) is the most widely used measure of cognitive performance in AD clinical trials. This key role has rightly brought its performance under increased scrutiny with recent research using traditional psychometric methods, questioning the ADAS-Cog's ability to adequately measure early-stage disease. However, given the limitations of traditional psychometric approaches, herein we use the more sophisticated Rasch Measurement Theory (RMT) methods to fully examine the strengths and weaknesses of the ADAS-Cog, and identify potential paths toward its improvement.
METHODS: We analyzed AD Neuroimaging Initiative (ADNI) ADAS-Cog data (675 measurements across four time-points over 2 years) from the AD participants. RMT analysis was undertaken to examine three broad areas: adequacy of scale-to-sample targeting; degree to which, taken together, the ADAS-Cog items adequately perform as a measuring instrument; and how well the scale measured the subjects in the current sample.
RESULTS: The 11 ADAS-Cog components mapped-out a measurement continuum, worked together adequately, and were stable across different time-points and samples. However, the scale did not prove to be a good match to the patient sample supporting previous research. RMT analysis also identified problematic "gaps" and "bunching" of the components across the continuum.
CONCLUSION: Although the ADAS-Cog has the building blocks of a good measurement instrument, this sophisticated analysis confirms limitations with potentially serious implications for clinical trials. Importantly, and unlike traditional psychometric methods, our RMT analysis has provided important clues aimed at solving the measurement problems of the ADAS-Cog. Crown
Copyright © 2013. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23253779     DOI: 10.1016/j.jalz.2012.08.006

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  19 in total

1.  An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease.

Authors:  Jessica B Langbaum; Suzanne B Hendrix; Napatkamon Ayutyanont; Kewei Chen; Adam S Fleisher; Raj C Shah; Lisa L Barnes; David A Bennett; Pierre N Tariot; Eric M Reiman
Journal:  Alzheimers Dement       Date:  2014-04-21       Impact factor: 21.566

2.  Dementia-Related Neuropsychological Testing Considerations in Non-Hispanic White and Latino/Hispanic Populations.

Authors:  Shanna L Burke; Mitra Naseh; Miriam J Rodriguez; Aaron Burgess; David Loewenstein
Journal:  Psychol Neurosci       Date:  2019-03-11

Review 3.  2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Jesse Cedarbaum; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Johan Luthman; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie Shaw; Li Shen; Adam Schwarz; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2015-06       Impact factor: 21.566

4.  Do antipsychotics lead to cognitive impairment in dementia? A meta-analysis of randomised placebo-controlled trials.

Authors:  Alexander Wolf; Stefan Leucht; Frank-Gerald Pajonk
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-08-16       Impact factor: 5.270

5.  Methodological Aspects of the Phase II Study AFF006 Evaluating Amyloid-beta -Targeting Vaccine AFFITOPE® AD02 in Early Alzheimer's Disease - Prospective Use of Novel Composite Scales.

Authors:  S Hendrix; N Ellison; S Stanworth; L Tierney; F Mattner; W Schmidt; B Dubois; A Schneeberger
Journal:  J Prev Alzheimers Dis       Date:  2015-06

6.  Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs.

Authors:  Holly Posner; Rosie Curiel; Chris Edgar; Suzanne Hendrix; Enchi Liu; David A Loewenstein; Glenn Morrison; Leslie Shinobu; Keith Wesnes; Philip D Harvey
Journal:  Innov Clin Neurosci       Date:  2017-02-01

Review 7.  Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Jesse Cedarbaum; Michael C Donohue; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie Shaw; Paul M Thompson; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2015-07       Impact factor: 21.566

8.  The Role of Entropy in Construct Specification Equations (CSE) to Improve the Validity of Memory Tests.

Authors:  Jeanette Melin; Stefan Cano; Leslie Pendrill
Journal:  Entropy (Basel)       Date:  2021-02-09       Impact factor: 2.524

Review 9.  Do cognitive interventions improve general cognition in dementia? A meta-analysis and meta-regression.

Authors:  J D Huntley; R L Gould; K Liu; M Smith; R J Howard
Journal:  BMJ Open       Date:  2015-04-02       Impact factor: 2.692

10.  Faster cognitive decline in the years prior to MR imaging is associated with smaller hippocampal volumes in cognitively healthy older persons.

Authors:  Debra A Fleischman; Lei Yu; Konstantinos Arfanakis; S Duke Han; Lisa L Barnes; Zoe Arvanitakis; Patricia A Boyle; David A Bennett
Journal:  Front Aging Neurosci       Date:  2013-06-05       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.